Success Stories: Thanks to the Expedited Service of USCIS, A Cardiovascular Medicine Fellow from Egypt Secured NIW Approval in Just 3 Days
Client’s Testimonial:
“Thank you so so much for all your help with my case, I am happy it worked out and very pleased with how quick the process was.”
On September 1st, 2023, we received another EB-2 NIW (National Interest Waiver) approval for a Cardiovascular Medicine Fellow in the Field of Cardiovascular Medicine (Approval Notice).
General Field: Cardiovascular Medicine
Position at the Time of Case Filing: Cardiovascular Medicine Fellow
Country of Origin: Egypt
State of Residence at the Time of Filing: Massachusetts
Approval Notice Date: September 1st, 2023
Processing Time: 3 days (Premium Processing Requested)
Case Summary:
After achieving over 32K approved cases, we are ecstatic that in this case also, we were able to get our client’s NIW approval without obstacles. Our client from Egypt works in the field of cardiovascular medicine and holds an MB BCh BAO degree. He planned to carry out more studies on developing treatment options and preventative measures for cardiovascular disease in order to provide accessible healthcare at the community level and improve population health.
After carefully examining our client's proposed research, we concluded that it is highly significant since it tackles a major global health issue. Consequently, we consented to countersign the client-attorney agreement and assist our client in obtaining the National Interest Waiver visa. We made sure to draw attention to a few key components in his NIW petition packet so that we could move his case forward in a meaningful way:
- Initially, we noted that his research has produced 13 peer-reviewed journal articles (1 of them first-authored), which have been published in no fewer than 3 highly ranked peer reviewed journals.
- We established that at the time of filing his NIW case, his work and research had 241 citations.
- In addition, there are significant ramifications for the US from our client’s suggested project as well. More than half of those with cardiovascular disease in America are under 60 years old, making up about 33% of the population. His efforts to develop treatments for cardiovascular disease directly benefit major healthcare sectors, like the U.S. biopharmaceutical sector, which generated trillions in revenue and carried out half of the world's research and development of new pharmaceuticals. Because cardiovascular disease is the primary cause of avoidable illness and death worldwide, our client’s work addresses this condition, which lessens the financial strain on the healthcare and economic sectors by preventing wasteful spending and lost productivity.